newsfilter
← Latest News
Business Wire·

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Successful First-In-Human Use of New Parenchymal Spinal Delivery System First-ever Administration of OPC1 to a Chronic Injury Patient Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a